报告发布方：中金企信国际咨询 项目可行性报告&商业计划书专业权威编制服务机构（符合发改委印发项目可行性研究报告编制要求）-中金企信国际咨询：集13年项目编制服务经验为各 类项目立项、投融资、商业合作、贷款、批地、并购&合作、投资决策、产业规划、境外投资、战略规划、风险评估等提供项目可行性报告&商业计划书编 制、设计、规划、咨询等一站式解决方案。助力项目实施落地、提升项目单位申报项目的通过效率。 （1）基因测序技术水平及特点： 1）基因测序技术发展概述：基因测序即通过采集生物的信息，分析其特定片段的碱基序列，并获得目的片段碱基排列顺序的技术，是进一步进行分子生物 学研究和基因改造的基础。1953年发现了DNA双螺旋结构，1990年人类基因组计划启动，推动了测序技术的快速发展，Sanger测序技术、NGS技术、单分子 测序相继问世。随着生物学、计算机科学、统计学等多学科相互促进迅速发展，测序价格大大降低及测序仪的能力越来越高，基因测序的应用领域不断拓 展，包括新药研发与创新、多组学研究、农林牧渔和环境保护等。 迄今为止，现有的基因测序技术可以根据其出现时间顺序划分为三个技术类别，每个技术都有各自的特点，互相补充， ...

Core Insights - The recent bio-manufacturing forum in Suzhou focuses on cutting-edge technologies and aims to facilitate technology transfer and industrial collaboration in the bio-manufacturing sector [1] - Bio-manufacturing is seen as a key driver of the "Fourth Industrial Revolution" and is crucial for developing new productive forces across various fields such as pharmaceuticals, agriculture, and food [1] - Suzhou Industrial Park is actively positioning itself in the bio-manufacturing sector, leveraging its strong industrial foundation and complete supply chain to seize development opportunities [1] Industry Development Plans - In March, Suzhou Industrial Park announced a three-year action plan to accelerate the development of the bio-manufacturing industry, focusing on synthetic biology, biopharmaceuticals, food, bio-based materials, and bio-manufacturing equipment [1][2] - The plan aims to enhance innovation capabilities, achieve scale effects, and improve the industrial ecosystem by 2027, with specific support in R&D, platform construction, innovation incubation, and collaborative development [2] Company Highlights - Suzhou has over 40 companies related to synthetic biology technology, accounting for nearly 60% of the total in the city [2] - Jinweizhi Biotechnology Co., Ltd. specializes in genomic research and technology applications, collaborating with 80% of the top 20 global pharmaceutical companies and serving multiple regions including China, North America, Europe, Southeast Asia, and Australia [2] - Jima Gene Co., Ltd. is a leading provider of RNA drug technology services in China, focusing on small nucleic acid technology and has established a pilot platform for nucleic acid drug research in collaboration with the National Biopharmaceutical Technology Innovation Center [3] Collaborative Models - The collaboration between national research centers and leading enterprises in Suzhou accelerates the overall industrial process of bio-manufacturing through a "national team + enterprise group" model [3] - The park plans to establish common technology platforms and resource libraries, including a microbial strain preservation library, to support high-throughput, intelligent, and automated pilot platforms [3]